ClinicalTrials.gg

Program

FGFR3/4 Inhibitor TYRA-430

Its studies are mostly in Carcinoma, Hepatocellular, led by Tyra Biosciences.

Furthest: phase 1, since Mar 31, 20251 company-led study, 1 open or runningNext primary completion: Jan 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tyra Biosciences11 open or runningphase 1since Mar 31, 2025Mar 31, 2025Jan 2028phase 1 · NCT06915753

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 31, 2025First study: phase 1 study in Carcinoma, HepatocellularFirst studyNCT06915753 · 125 planned · United States, Canada, South Korea and more

Ahead

  1. Jan 2028Primary completion: phase 1 study in Carcinoma, HepatocellularNCT06915753

TargetBeta

FGFR3 →read by rule
“An orally bioavailable reversible inhibitor of fibroblast growth factor receptor (FGFR) types 3 and 4 (FGFR3/4), ”NCIt, by rule

Other programs on FGFR3

ProgramCompanyFurthest phaseStudies
nintedanibruleBoehringer Ingelheimphase 476
masitinibruleAB Sciencephase 338
infigratinibruleBridgeBiophase 317
pemigatinibruleIncytephase 316
futibatinibruleOtsukaphase 310
vepugratinibruleEli Lillyphase 35
dabogratinibruleTyra Biosciencesphase 25
Anti-FGFR3 Antibody-drug Conjugate BHV-1530rulebiohaven-therapeutics-ltdphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06915753Carcinoma, Hepatocellular · United States, Canada, South Korea and more1RecruitingJan 2028125

How it is read

Names in the registry

  • “TYRA-430”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.